Project Grant R15CA274493
Award Date
9/19/23
Completion Date
8/31/26
Dollars Obligated
$387K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Geneva, NY 14456, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $661,122 in funding to The Trustees of Columbia University in the City of New York to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to evaluate whether the accumulation of delta-2 tubulin, an irreversible tubulin modification, plays a common pathogenic role in the neuropathic...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Institute of General Medical Sciences (NIGMS) awarded a $500,681 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to the Research Foundation of the City University of New York (RFCUNY). The grant aims to investigate the role of microtubule phosphorylation as a "toggle switch" governing cancer-related cell proliferation and motility in human breast cancer. Key activities include molecular dynamics simulations, in vitro experiments with...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $196,267 in funding to the University of California, Irvine (UCI) to advance novel cancer prevention and therapeutic strategies across NCI's clinical trial networks. The award will support the Principal Investigator's leadership roles on key NCI committees, completion of an ongoing Phase III clinical trial focused on preventing colorectal adenomas in a racially/ethnically...
This $429,123 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of improved inhibitors that selectively target the CBX8 chromatin reader domain. The research team at Purdue University is using DNA-encoded library screening approaches to identify CBX8-selective inhibitors with enhanced cellular activity compared to current probes. The goal is to validate the selective inhibition of CBX8 as a viable, non-toxic therapeutic...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme for the treatment of hepatocellular carcinoma (HCC). The research aims to identify potent and specific CYP8B1 inhibitors through high-throughput screening, validate their potency and selectivity, and elucidate the...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $585,931 to the University of Pittsburgh to conduct research on evaluating and selecting representative cancer models for precision medicine. The key objectives are to: (1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer; (2) perform subclone-based congruence and selection for cancer models; and (3) decipher temporal changes in...
The National Cancer Institute (NCI) awarded a $432,614 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Duke University. The grant, awarded on September 1, 2024, will support research to define the relationship between chromosomal instability (CIN), loss of the short arm of chromosome 17 (17P loss), and sensitivity to inhibition of the mitotic regulator NDE1. The research aims to characterize the role of NDE1 in proper chromosome segregation and assess the therapeutic...
The National Cancer Institute (NCI) awarded a $230,711 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research aimed at overcoming resistance to Hedgehog inhibition therapies in basal cell carcinomas (BCCs). The research will focus on elucidating the role of the BRD9 chromatin remodeling protein in promoting an immunosuppressive tumor microenvironment, which contributes to Hedgehog...